The FDA has approved Apellis Pharmaceuticals’ EMPAVELI as the first treatment for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis in patients 12 and older, affecting 5,000 people in the US. The approval is based on positive results from the VALIANT study, showing benefits across all key disease markers. Common adverse reactions include infusion site reactions, pyrexia, nasopharyngitis, influenza, cough, and nausea. For more health news, visit rttnews.com. (Source: RTTNews)

Read more at Nasdaq: Apellis Pharma Secures FDA Approval For EMPAVELI To Treat Rare Kidney Disorders